Halozyme Therapeutics (HALO) Gross Profit Growth (1y) (2011 - 2026)

Halozyme Therapeutics (HALO) Gross Profit Growth (1y) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gross Profit Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 41.37%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 7.76%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 16.94%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 68.41%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Halozyme Therapeutics 9.65 Bn 9.33 Bn 297.47 Mn 37.43%

Historic Data

Download Data
DateValue
Mar 31, 2026 37.43%
Dec 31, 2025 45.73%
Sep 30, 2025 24.25%
Jun 30, 2025 45.69%
Mar 31, 2025 29.19%
Dec 31, 2024 44.00%
Sep 30, 2024 49.28%
Jun 30, 2024 12.15%
Mar 31, 2024 31.96%
Dec 31, 2023 27.53%
Sep 30, 2023 -0.28%
Jun 30, 2023 44.37%
Mar 31, 2023 25.27%
Dec 31, 2022 73.32%
Sep 30, 2022 66.24%
Jun 30, 2022 4.39%
Mar 31, 2022 43.15%
Dec 31, 2021 -15.73%
Sep 30, 2021 62.75%
Jun 30, 2021 129.25%